Enovis Co. (NYSE:ENOV) Given Consensus Recommendation of “Moderate Buy” by Brokerages

Shares of Enovis Co. (NYSE:ENOV) have been given a consensus recommendation of “Moderate Buy” by the eight research firms that are presently covering the company, Marketbeat reports. One investment analyst has rated the stock with a hold rating and seven have assigned a buy rating to the company. The average twelve-month target price among brokers that have issued ratings on the stock in the last year is $67.00.

A number of analysts have recently issued reports on ENOV shares. Evercore ISI cut their price target on shares of Enovis from $62.00 to $58.00 and set an “outperform” rating for the company in a report on Tuesday, October 1st. Needham & Company LLC reiterated a “buy” rating and set a $65.00 target price on shares of Enovis in a report on Thursday, November 7th. Finally, JMP Securities started coverage on shares of Enovis in a research note on Thursday, October 3rd. They set an “outperform” rating and a $62.00 target price on the stock.

Institutional Investors Weigh In On Enovis

Several hedge funds and other institutional investors have recently added to or reduced their stakes in ENOV. First Eagle Investment Management LLC increased its holdings in shares of Enovis by 13.3% in the 2nd quarter. First Eagle Investment Management LLC now owns 284,596 shares of the company’s stock valued at $12,864,000 after acquiring an additional 33,300 shares during the last quarter. Sei Investments Co. boosted its holdings in shares of Enovis by 50.9% in the second quarter. Sei Investments Co. now owns 223,358 shares of the company’s stock valued at $10,096,000 after acquiring an additional 75,317 shares in the last quarter. Confluence Investment Management LLC acquired a new position in Enovis during the fourth quarter worth about $3,494,000. King Luther Capital Management Corp raised its holdings in shares of Enovis by 45.2% in the 2nd quarter. King Luther Capital Management Corp now owns 177,862 shares of the company’s stock worth $8,039,000 after purchasing an additional 55,385 shares in the last quarter. Finally, Chartwell Investment Partners LLC boosted its position in shares of Enovis by 25.6% in the 3rd quarter. Chartwell Investment Partners LLC now owns 201,652 shares of the company’s stock valued at $8,681,000 after purchasing an additional 41,089 shares during the period. Hedge funds and other institutional investors own 98.45% of the company’s stock.

Enovis Stock Up 2.1 %

ENOV stock opened at $45.70 on Thursday. The firm’s fifty day simple moving average is $45.89 and its 200-day simple moving average is $44.33. The company has a market capitalization of $2.55 billion, a P/E ratio of -20.87 and a beta of 1.94. Enovis has a 12 month low of $38.27 and a 12 month high of $65.03. The company has a debt-to-equity ratio of 0.40, a current ratio of 2.27 and a quick ratio of 1.12.

Enovis (NYSE:ENOV) last announced its earnings results on Wednesday, November 6th. The company reported $0.73 earnings per share for the quarter, topping the consensus estimate of $0.62 by $0.11. Enovis had a positive return on equity of 4.39% and a negative net margin of 5.95%. The business had revenue of $505.22 million during the quarter, compared to the consensus estimate of $504.44 million. During the same period in the prior year, the company posted $0.56 EPS. The business’s quarterly revenue was up 21.0% on a year-over-year basis. As a group, equities research analysts forecast that Enovis will post 2.79 earnings per share for the current year.

Enovis Company Profile

Enovis Corporation operates as a medical technology company focus on developing clinically differentiated solutions worldwide. It also manufactures and distributes medical devices which are used for reconstructive surgery, rehabilitation, pain management, and physical therapy. The company operates through Prevention and Recovery, and Reconstructive segments.